Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer

Published:2022-05-08 Issue:1 Volume:25 Page:591-604
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Berdunov Vladislav¹^ORCID,Millen Steve²,Paramore Andrew²^ORCID,Hall Peter³^ORCID,Perren Timothy⁴,Brown Rebecca¹,Griffin Jane⁵,Reynia Sarah²,Fryer Nina²,Longworth Louise¹

Affiliation:

1. PHMR Ltd, London, UK

2. Exact Sciences, London, UK

3. Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK

4. Leeds Teaching Hospitals NHS Trust, Leeds, UK

5. Jane Griffin Associates, East Molesey, UK

Funder

Exact Sciences

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2066399

Reference44 articles.

1. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)

2. Early and locally advanced breast cancer: diagnosis and management NICE guideline [Internet]; 2018; [cited 2020 Aug 14]. Available from: www.nice.org.uk/guidance/ng101

3. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer

4. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

5. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective;ClinicoEconomics and Outcomes Research;2024-06

2. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands;Journal of Medical Economics;2024-03-12

3. Multimodal histopathologic models stratify hormone receptor-positive early breast cancer;2024-02-28

4. The role of modern parameters and their relationship with recurrence risk as assessed by Oncotype DX: real-world evidence;ecancermedicalscience;2024-02-06

5. Comprehensive insight on managing tissues and cell samples with tissue banking practices;Reference Module in Chemistry, Molecular Sciences and Chemical Engineering;2024